-
Mashup Score: 7
Objective To evaluate the dose-response relationship of 10, 20, and 40 mg ponesimod and long-term efficacy and safety of ponesimod 20 mg using an analysis of combined data from the phase 2 Core and Extension studies in patients with relapsing-remitting multiple sclerosis (RRMS). Methods In the Core study, 464 patients were randomized (1:1:1:1): placebo (n = 121), 10 mg (n = 108), 20 mg (n =…
Source: NeurologyCategories: Latest Headlines, NeurologyTweet
-
Mashup Score: 0Ponesimod Treatment in Early Multiple Sclerosis Reduced Likelihood of Severe Relapses and Was Safe in Long-Term Studies - Practical Neurology - 2 year(s) ago
As previously reported, ponesimod (Ponvory; Janssen Pharmaceuticals, Titusville, NJ) significantly reduced the annualized rate of relapse (ARR) in rel
Source: Practical NeurologyCategories: Latest Headlines, NeurologyTweet
-
Mashup Score: 0
Researchers sought to determine whether patients who discontinued treatment with ponesimod had an increased risk for MS disease activity exacerbation.
Source: Neurology AdvisorCategories: Latest Headlines, NeurologyTweet
-
Mashup Score: 2FDA Clears Ponesimod (Ponvory), New Oral Drug for MS - 3 year(s) ago
The selective sphingosine-1-phosphate receptor 1 modulator for adults with relapsing forms of MS proved superior to teriflunomide in a phase 3, 2-year, head-to-head comparative study.
Source: MedscapeCategories: Latest Headlines, NeurologyTweet
-
Mashup Score: 2
A new drug application (NDA) for ponesimod (Janssen Pharmaceutical, Titusville, NJ) for the treatment of adults with relapsing multiple sclerosis (MS)
Source: Practical NeurologyCategories: NeurologyTweet
Long-term Treatment With #Ponesimod in Relapsing-Remitting #MultipleSclerosis: Results From Randomized Phase 2b Core and Extension Studies https://t.co/DSGdSnsEck #NeuroTwitter #MS https://t.co/XSJ5kdWPEq